Research programme: Ebola virus vaccine - Pentamer Pharmaceuticals

Drug Profile

Research programme: Ebola virus vaccine - Pentamer Pharmaceuticals

Alternative Names: Ebola DNA vaccine - Pentamer Pharmaceuticals; Ebola peptide vaccine - Pentamer Pharmaceuticals

Latest Information Update: 17 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pentamer Pharmaceuticals
  • Class DNA vaccines; Peptide vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Ebola virus infections

Most Recent Events

  • 16 Oct 2014 Research programme: Ebola virus vaccine - Pentamer Pharmaceuticals is available for licensing as of 16 Oct 2014. http://www.pentamerpharma.com/
  • 14 Oct 2014 Preclinical trials in Ebola virus infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top